The boards of biotechnology companies have reaffirmed their will to shape the further development of the biotech industry as an economically sound and innovative sector.
Following the ruling by the Federal Constitutional Court on the case by the Federal State of Saxony-Anhalt against the Law on Genetic Engineering, BIO Deutschland has called for a rational approach to plant biotechnology.
In order to unleash its entire potential and to make a strong contribution to Germany’s economy, white biotechnology, as a cornerstone of the bio-economy, needs political support and internationally competitive parameters.
Over 35 experts met during BIO-Europe in Munich in the middle of November to found a new BIO Deutschland Working Group on Communication and Public Relations.
The members of the Working Group on Diagnostics met in Munich on 15 November 2010 during BIO-Europe.
The board of BIO Deutschland met for its fourth meeting in 2010 after the Twelfth CEO & CFO Meeting in Hamburg on 26 November.
The sector association of the biotechnology industry, BIO Deutschland, welcomes the National Research Strategy, BioEconomy 2030.
BIO Deutschland has criticised that medication for rare diseases (so-called orphan drugs) will only be exempt from benefit assessment up to a turnover of €50 million.
In the middle of November, BIO Deutschland presented its work at a stand at BIO-Europe in Munich, where it introduced over 40 member companies (which had registered in advance) in the form of short electronic presentations.
Biotechnology is also increasingly in demand in climate and resource protection. At the beginning of November, BioTOP Berlin-Brandenburg organised a discussion on technology policy in Potsdam in cooperation with the Fraunhofer Institute for Applied Polymer Research (IAP), the Leibniz Centre for Agricultural Land Research (ZALF) and the University of Potsdam, among others, with the aim of covering the key points for the future development of the bio-economy in the region.